Board and Management

Board and management

Management team

maria-engstrom-cfo

Christer Ahlberg

Chief Executive Officer and Co-Founder

  • Born: 1971
  • Nationality: Swedish
  • Position: President and Chief Executive Officer of Cinclus Pharma since June 2021, employed since 2021.
  • Education and professional experience: Christer holds a BSc in business administration and economics from Örebro University. Former experience in the pharmaceutical industry includes CEO at Sedana Medical Group (publ) (2017-2021) and CEO at Unimedic Group (2010–2016), CEO at Eisai AB (2005–2010) and more than 10 years of experience in leading positions in sales and marketing at e.g. AstraZeneca (including launch of Nexium), Meda and Wyeth.
  • Other current engagements: Board member in FrostPharma AB, Prooxpharma AB and Glycorex Transplantation AB. CEO and deputy board member in Waxholm by the sea AB.

Gösta Hiller

Chief Operating Officer

  • Born: 1968

  • Nationality: Swedish

  • Education and professional experience: Gösta holds a PhD in Cell-and Molecular Biology from Lund University. Former experience in the pharmaceutical industry includes CEO, COO and Clinical Advisor at SDS Life Science (2017-2021), Clinical- and Global Project Manager and Scientist in different positions at AstraZeneca R&D (2001 -2012). He brings almost 20 years of experience from drug development and project management.

Kjell Andersson, PhD

Chief Scientific Officer and Co-Founder

  • Ph.D. Pharmacologist with 30 years’ of experience from Astra/AstraZeneca

  • Preclinical project leader for Losec, the first PPI on the market

  • Preclinical project leader for Nexium including clinical, marketing

    and regulatory support

  • Discovery project leader on the P-CAB program bringing linaprazan through the phase II studies

Peter Unge, MD, PhD

Chief Medical Officer, Board Director and Co-Founder

  • MD. Ph.D. Gastroenterologist with 25 years’ of Healthcare experience
  • Developed the first modern H. pylori eradication therapy principles  
  • Supported sNDAs and medical affairs at AstraZeneca for 13 years
  • Novartis HQ in Basel, Switzerland for 12 years in drug development
  • Assigned as VP and Head of the Scientific Office, SOP and Training compliance Offices

Maria Engström

Chief Financial Officer

  • Born: 1972
  • Nationality: Swedish  
  • Position: Chief Financial Officer of Cinclus Pharma since August 2021.
  • Education and professional experience: Maria holds a BSc in Business Administration and Economics from Stockholm University. She was formerly the CFO of Sedana Medical Group (2017-2021) and Managing Director at Cross Pharma AB (2015–2016). Maria has also extensive experience from leading positions within finance for the past 20 years within Medivir, Biovitrum, Bristol Myers Squibb and Ericsson.

  • Other current engagements: Board Member in her own consultant company FAYSIT – Finance At Your Service In Tyresö AB and Advisory board member in Ugglapraktiken AB.

Board of Directors

Lennart Hansson, PhD 

Chairman of the Board and Co-Founder

  • Ph.D. in Genetics. More than 25 years’ experience in senior executive positions for R&D and business development in pharmaceutical- and biotech industry, including KabiGen, Symbicom, AstraZeneca, Biovitrum and Arexis
  • Has filed more than 20 patent applications and published more than 50 scientific papers
  • For the last nine years he has been active in venture capital investments in Life Science
  • Served as Board director in more than 25 life science companies

Wenche Rolfsen, PhD, Professor

Board Director

  • Ph.D in Pharmacology. More than 30 years in drug discovery and development from Pharmacia and Quintiles

  • Over the last 15 years, she has been on the Board of many life Science companies, private, governmentally owned and publicly listed in Norway, UK and Sweden

  • Currently active as Chairman of InDex Pharmaceuticals and BioArctic and member of the Board of Swedish Match and InDex Diagnostics. CEO and Board member of Rolfsen Consulting AB. Partner in Serendipity Partners.

Torbjörn Koivisto

Board Director 

  • More than 10 years’ experience as a business lawyer from law firms Mannheimer Swartling, Lindahl and Bird & Bird
  • Since 2006 working for his own company IARU, advising clients within the life sciences industry on matters of commercial and corporate law
  • He is currently active as a member of the Board of Xspray Pharma and Hemcheck Sweden

Peter Unge, MD, PhD

Board Director, Chief Medical Officer and Co-Founder

  • MD. Ph.D. Gastroenterologist with 25 years’ of Healthcare experience
  • Developed the first modern H. pylori eradication therapy principles
  • Supported sNDAs and medical affairs at AstraZeneca for 13 years
  • Novartis HQ in Basel, Switzerland for 12 years in drug development
  • Assigned as VP and Head of the Scientific Office, SOP and Training compliance Offices

Anders Öhberg, M.Sc.

Board Director

  • More than 12 years experience from drug development and medical affairs within the pharmaceutical industry

  • He has held a broad a spectrum of positions within clinical development, pharmacovigilance, quality assurance and medical affairs at Pfizer, Ipsen, Shire and Novartis

  • Currently heading the Nordic medical affairs business for gene therapy at Novartis within rare ophthalmology. Anders holds a
    master’s degree in medical sciences and clinical drug development from Uppsala University 

Helena Levander, M.Sc.

Board Director

  • Master in Finance and Business Administration from Stockholm School of Economics. More than 20 years of experience within asset management and equity markets from SEB, Nordea, Odin Funds and Neonet Securities.
  • Owner and chair of Nordic Investor Services, a leading proxy advisor and corporate governance consultant, for nearly 20 years.
  • Over the last 20 years board member of several Nordic companies in different industries. Within life science, board experience
    as chair of Medivir and member of Abliva and Recipharm.
  • Today a board member of Rejlers, Stendörren Fastigheter, Lannebo Fonder, Factoringgruppen, Concordia Maritime and Occlutech.